Leslie M. Hutchins, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 102 N Magdalen St, San Angelo, TX 76903 Phone: 325-658-1511 Fax: 325-481-2166 |
Christopher W Vanderzant, DO Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 E Beauregard Ave, San Angelo, TX 76903 Phone: 325-658-1511 |
Timothy E Hopkins, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 102 N Magdalen St, San Angelo, TX 76903 Phone: 325-658-1511 |
Dr. Joseph Kyle Hobbs, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 102 N Magdalen St, San Angelo, TX 76903 Phone: 325-747-2193 |
Luis E Duarte, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 E Beauregard Ave, San Angelo, TX 76903 Phone: 325-658-1511 |
Mr. Duncan Kinnear Fischer, MD PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3515 Executive Dr, San Angelo, TX 76904 Phone: 325-947-2525 Fax: 325-947-1139 |
Dr. Robert H Legrand, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 211 E College Ave, San Angelo, TX 76903 Phone: 325-655-4164 |
News Archive
BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).
Drones have become ubiquitous in our society; there is a national drone film festival, a national drone racing championship, and drones are being used extensively by the military for surveillance.
Researchers at the University of Texas Medical Branch at Galveston (UTMB) have developed a new way to predict the ability of certain small molecules to protect proteins in the cells of a wide variety of organisms living in extreme environments.
Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.
› Verified 6 days ago